News
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Immunic, Inc. (Nasdaq: IMUX) to release Q3 financial results and corporate update on Nov 7, 2024. Webcast at 8:00 am ET. Company developing therapies for inflammatory and autoimmune diseases. Visit www.imux.com for more info -
-
-
COMMUNIQUÉ DE PRESSE
Immunic to Participate in Industry, Scientific and Investor Conferences in November
Immunic to participate in industry, scientific, and investor conferences in November 2024, presenting data on IMU-856 for celiac disease. Details on events and presentations available on company website -
-
-
COMMUNIQUÉ DE PRESSE
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Immunic announces positive outcome of interim analysis of Phase 3 ENSURE Program for vidofludimus calcium in RMS. Trials recommended to continue unchanged till 2026 -
